Seelos Therapeutics Inc SEEL:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 08/17/22 EDT
0.95quote price arrow up+0.02 (+2.15%)
Volume
531
Close
0.93quote price arrow up+0.006 (+0.65%)
Volume
291,488
52 week range
0.48 - 2.79
Loading...
  • Open0.92
  • Day High0.9581
  • Day Low0.92
  • Prev Close0.93
  • 52 Week High2.79
  • 52 Week High Date09/29/21
  • 52 Week Low0.48
  • 52 Week Low Date05/12/22

Key Stats

  • Market Cap99.22M
  • Shares Out106.69M
  • 10 Day Average Volume0.71M
  • Dividend-
  • Dividend Yield-
  • Beta2.47
  • YTD % Change-42.94

KEY STATS

  • Open0.92
  • Day High0.9581
  • Day Low0.92
  • Prev Close0.93
  • 52 Week High2.79
  • 52 Week High Date09/29/21
  • 52 Week Low0.48
  • 52 Week Low Date05/12/22
  • Market Cap99.22M
  • Shares Out106.69M
  • 10 Day Average Volume0.71M
  • Dividend-
  • Dividend Yield-
  • Beta2.47
  • YTD % Change-42.94

RATIOS/PROFITABILITY

  • EPS (TTM)-0.70
  • P/E (TTM)-1.33
  • Fwd P/E (NTM)-2.00
  • EBITDA (TTM)-73.533M
  • ROE (TTM)-134.67%
  • Revenue (TTM)0.00
  • Gross Margin (TTM)79.21%
  • Net Margin (TTM)-5,984.27%
  • Debt To Equity (MRQ)73.44%

EVENTS

  • Earnings Date11/08/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Seelos Therapeutics Inc

There is no recent news for this security.

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of products that address unmet needs in central nervous system (CNS) disorders and other rare disorders. The Company's lead programs SLS-002 for the treatment of acute suicidal ideation and behavior (ASIB) in depressive disorder (MDD), and SLS-005 for the potential treatment of amyotrophic lateral sclerosis (ALS). SLS-005 for the potential treatment of Sanfilippo...
Raj Mehra Ph.D.
Chairman of the Board, President, Chief Executive Officer
Michael Golembiewski
Chief Financial Officer
Address
300 PARK AVENUE, 2ND FLOOR
New York, NY
10022
United States

Top Peers

SYMBOLLASTCHG%CHG
INFI
Infinity Pharmaceuticals Inc
1.49-0.04-2.61%
SCYX
SCYNEXIS Inc
2.93+0.04+1.38%
GTBP
GT Biopharma Inc
2.64+0.01+0.38%
ZYNE
Zynerba Pharmaceuticals Inc
1.32-0.01-0.75%
AVTX
Avalo Therapeutics Inc
5.07-0.16-3.06%